Literature DB >> 15556994

Sarcolipin retention in the endoplasmic reticulum depends on its C-terminal RSYQY sequence and its interaction with sarco(endo)plasmic Ca(2+)-ATPases.

Anthony O Gramolini1, Thomas Kislinger, Michio Asahi, Wenping Li, Andrew Emili, David H MacLennan.   

Abstract

Sarcolipin (SLN) and phospholamban (PLN) are effective inhibitors of the sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA). These homologous proteins differ at their N and C termini: the C-terminal Met-Leu-Leu in PLN is replaced by Arg-Ser-Tyr-Gln-Tyr in SLN. The role of the C-terminal sequence of SLN tagged N-terminally with the FLAG epitope (NF-SLN) in endoplasmic reticulum (ER) retention was investigated by transfecting human embryonic kidney-293 cells with cDNAs encoding NF-SLN or a series of NF-SLN mutants in which C-terminal amino acids were deleted progressively. Immunofluorescence and immunoblotting of transfected cells by using anti-FLAG antibodies indicated that NF-SLN and PLN tagged at its N terminus with the FLAG epitope, even when overexpressed, were restricted to the ER. However, C-terminal truncation deletions of SLN, which lacked RSYQY, were not localized to ER and did not inhibit Ca(2+)-dependent Ca2+ uptake by SERCA. The shortest deletion constructs, NF-SLN 1-22 and NF-SLN 1-23, did not express stable protein products. However, all NF-SLN cDNA constructs, including NF-SLN 1-22 and NF-SLN 1-23, were expressed stably and localized to the ER when they were coexpressed with SERCA2a. These results show that NF-SLN subcellular distribution depends on SERCA coexpression and on its luminal, C-terminal RSYQY sequence. By using immunoprecipitation and MS, glucose-regulated protein 78/BiP and glucose-regulated protein 94 were identified as proteins that interact with NF-SLN through the RSYQY sequence. Thus, in the absence of SERCA, retention of NF-SLN in the ER is mediated through its association with other components through the C-terminal RSYQY sequence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556994      PMCID: PMC534750          DOI: 10.1073/pnas.0407815101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites.

Authors:  M Asahi; Y Kimura; K Kurzydlowski; M Tada; D H MacLennan
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

2.  Sarco/endoplasmic-reticulum calcium ATPase SERCA1 is maintained in the endoplasmic reticulum by a retrieval signal located between residues 1 and 211.

Authors:  Thomas Newton; John P J Black; John Butler; Anthony G Lee; John Chad; J Malcolm East
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

Review 3.  TRP channels as cellular sensors.

Authors:  David E Clapham
Journal:  Nature       Date:  2003-12-04       Impact factor: 49.962

4.  PRISM, a generic large scale proteomic investigation strategy for mammals.

Authors:  Thomas Kislinger; Khaled Rahman; Dragan Radulovic; Brian Cox; Janet Rossant; Andrew Emili
Journal:  Mol Cell Proteomics       Date:  2003-02-10       Impact factor: 5.911

5.  Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/peptide-binding protein 74 (PBP74) and GRP94.

Authors:  S Takano; R Wadhwa; Y Mitsui; S C Kaul
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

6.  Structure and orientation of sarcolipin in lipid environments.

Authors:  Alessandro Mascioni; Christine Karim; George Barany; David D Thomas; Gianluigi Veglia
Journal:  Biochemistry       Date:  2002-01-15       Impact factor: 3.162

7.  Sarcolipin inhibits polymerization of phospholamban to induce superinhibition of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs).

Authors:  Michio Asahi; Kazimierz Kurzydlowski; Michihiko Tada; David H MacLennan
Journal:  J Biol Chem       Date:  2002-05-24       Impact factor: 5.157

8.  Sarcolipin regulates sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban.

Authors:  Michio Asahi; Yuji Sugita; Kazimierz Kurzydlowski; Stella De Leon; Michihiko Tada; Chikashi Toyoshima; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-11       Impact factor: 11.205

9.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase.

Authors:  Chikashi Toyoshima; Michio Asahi; Yuji Sugita; Reena Khanna; Takeo Tsuda; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

View more
  27 in total

1.  Tilt and azimuthal angles of a transmembrane peptide: a comparison between molecular dynamics calculations and solid-state NMR data of sarcolipin in lipid membranes.

Authors:  Lei Shi; Alessandro Cembran; Jiali Gao; Gianluigi Veglia
Journal:  Biophys J       Date:  2009-05-06       Impact factor: 4.033

2.  Metformin increases degradation of phospholamban via autophagy in cardiomyocytes.

Authors:  Allen C T Teng; Tetsuaki Miyake; Shunichi Yokoe; Liyong Zhang; Luís Mário Rezende; Parveen Sharma; David H MacLennan; Peter P Liu; Anthony O Gramolini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

3.  Oligomeric interactions of sarcolipin and the Ca-ATPase.

Authors:  Joseph M Autry; John E Rubin; Sean D Pietrini; Deborah L Winters; Seth L Robia; David D Thomas
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 4.  The Ca2+ pumps of the endoplasmic reticulum and Golgi apparatus.

Authors:  Ilse Vandecaetsbeek; Peter Vangheluwe; Luc Raeymaekers; Frank Wuytack; Jo Vanoevelen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

Review 5.  Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the Sarco(Endo)Plasmic Reticulum Calcium ATPase?

Authors:  Sana A Shaikh; Sanjaya K Sahoo; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

6.  Sarcolipin protein interaction with sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) is distinct from phospholamban protein, and only sarcolipin can promote uncoupling of the SERCA pump.

Authors:  Sanjaya K Sahoo; Sana A Shaikh; Danesh H Sopariwala; Naresh C Bal; Muthu Periasamy
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

7.  Threonine-5 at the N-terminus can modulate sarcolipin function in cardiac myocytes.

Authors:  Poornima Bhupathy; Gopal J Babu; Makoto Ito; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2009-07-23       Impact factor: 5.000

8.  Pulmonary artery banding alters the expression of Ca2+ transport proteins in the right atrium in rabbits.

Authors:  Subash C Gupta; Kenneth D Varian; Naresh C Bal; Jessica L Abraham; Muthu Periasamy; Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-17       Impact factor: 4.733

9.  Identification of Small Ankyrin 1 as a Novel Sarco(endo)plasmic Reticulum Ca2+-ATPase 1 (SERCA1) Regulatory Protein in Skeletal Muscle.

Authors:  Patrick F Desmond; Joaquin Muriel; Michele L Markwardt; Mark A Rizzo; Robert J Bloch
Journal:  J Biol Chem       Date:  2015-09-24       Impact factor: 5.157

10.  Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology.

Authors:  Gopal J Babu; Poornima Bhupathy; Cynthia A Carnes; George E Billman; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2007-05-18       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.